V-Wave’s implantable unidirectional inter-atrial shunt is designed to regulate Left Atrial Pressure (LAP), an important underlying cause of worsening Heart Failure (HF).
V-Wave develops percutaneous implantable therapeutic devices for chronic Heart Failure (HF) patients. Based in Israel, our team has a track record of multiple successes in early-stage companies.
Unique Design for Safe and Effective LAP RegulationThe V-Wave Shunt is a miniature, biocompatible inter-atrial unidirectional implant, presenting a novel therapeutic approach for patients with chronic HF.
The shunt regulates LAP, the cause of worsening symptoms that lead to over 3 million hospitalizations a year. It is designed to prevent episodes of elevated LAP and thus improve symptoms, reduce hospitalizations, improve exercise tolerance and quality of life.
V-Wave shunt is currently under investigation in multiple clinical trials in North America, Europe and Israel.
V-Wave Ltd. is a privately held company with offices in Israel and the US. The company is focused on developing percutaneous implantable devices for treating patients with chronic Heart Failure (HF).
As a leading cause of death and hospitalization, HF continues to affect millions of people worldwide. V-Wave’s vision is to help patients who remain with disabling symptoms or need hospitalization despite optimized medical treatment.
V-Wave has developed a proprietary unidirectional inter-atrial shunt intended to relieve symptoms, reduce hospitalization, increase exercise capacity and improve the overall quality of life.
The original concept and development started in Israel with a talented team of engineers and medical scientists. The company’s senior management has decades of experience successfully developing, clinically testing and bringing to market multiple implantable cardiovascular devices.
Dr. Eigler, originally trained in systems engineering at UCLA, attended Yale Medical School and was a Cardiovascular Fellow at Cedars-Sinai Hospital. Alongside Dr. Litvack, he served as Co-Director of Cardiac Intervention at Cedars-Sinai for more than two decades, holding the academic rank of Professor of Medicine at UCLA.
Dr, Eigler has 41 issued U.S. patents for medical devices. He was a Co-Founder and/or Medical Director of Progressive Angioplasty System (PAS) and Conor MedSystems, where he co-invented the multi-drug delivery stent platform with programmable elution kinetics.
In 2000, Dr. Eigler founded and served as CEO at Savacor, a developer of an implantable left atrial pressure sensing system that was linked to a real-time patient self-management system for treating HF. After the acquisition of the company, he remained with St. Jude (acquiring company) as a Senior Vice President of Technology Incubation from 2006 through 2014.
Mr. Rozenfeld has a proven track record in successful initiation and execution of high-return global business development plans in the field of medical devices. He has implemented new business models and strategic plans, overseen mergers and acquisitions, and helped medical innovation companies engage new markets, globally.
Mr. Rozenfeld served as Managing Director at Lumenis UK ,as well as in key managerial positions for publicly traded companies, including Teva Group and Agis.
Furthermore, Mr. Rozenfeld has vast experience managing emerging companies as Senior VP global operations at Aesthera Inc., CEO of RapiX and as CEO of V-Wave prior to global expansion.
Mr. Rozenfeld holds an Executive MBA and BA from Bar Ilan University, Israel.
Prof. Abraham is director of the Division of Cardiovascular Medicine and a professor of internal medicine, physiology and cell biology at The Ohio State University Wexner Medical Center.
He also serves as Associate Director for Clinical and Translational Research at the Dorothy M. Davis Heart and Lung Research Institute.
Prof. Abraham is an internationally known researcher in heart failure. His research interests include hemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation.
Prof. Abraham has participated as a site principal investigator in more than 100 multicenter clinical drug and device trials. He has also served as national or international principal investigator and on the steering committees of more than 30 multicenter clinical drug and device trials.
Dr. Litvack received his MD from McGill University and was trained in Cardiology at Cedars-Sinai Hospital, where he remained as Co-Director of the Cardiovascular Intervention Center for 15 years. He has co-founded, operated and served as Chairman of a number of innovative Medtech companies including:
– Chairman of Progressive Angioplasty System (PAS), the developer of the stent delivery system for the original Palmaz-Schatz stent and other products. PAS was acquired by U.S. Surgical in 1997.
– CEO and Chairman of Conor MedSystems, a developer of innovative drug eluting stent technology. Dr Litvack took Conor public in 2005 and it was later acquired by Johnson & Johnson in 2007.
– Chairman of Savacor, a left atrial pressure monitoring company that was acquired by St. Jude Medical in 2005.
Dr. Litvack currently serves on several Boards and is Chairman of Capricor Inc., a biotechnology company focusing on cardiovascular diseases. He is also a Founding Partner of Pura Vida Funds LLC, a healthcare investment firm.
Dr. Eigler, originally trained in systems engineering at UCLA, attended Yale Medical School and was a Cardiovascular Fellow at Cedars-Sinai Hospital. Alongside Dr. Litvack, he served as Co-Director of Cardiac Intervention at Cedars-Sinai for more than two decades, holding the academic rank of Professor of Medicine at UCLA.
Dr, Eigler has 41 issued U.S. patents for medical devices. He was a Co-Founder and/or Medical Director of Progressive Angioplasty System (PAS) and Conor MedSystems, where he co-invented the multi-drug delivery stent platform with programmable elution kinetics.
In 2000, Dr. Eigler founded and served as CEO at Savacor, a developer of an implantable left atrial pressure sensing system that was linked to a real-time patient self-management system for treating HF. After the acquisition of the company, he remained with St. Jude (acquiring company) as a Senior Vice President of Technology Incubation from 2006 through 2014.
Dr. Shmulewitz has more than twenty years of experience as a physician, scientist, inventor, founder, and executive with a positive track record in the US, Europe, and Israel.
Dr. Shmulewitz graduated medical school cum laude from the Technion and holds a Ph.D. in Engineering from Tel-Aviv University.
Mr. Maor, Partner at BRM, is responsible for life science investments in the firm. He has an extensive background in healthcare as a senior executive with over 22 years experience in the medical device business.
Mr. Maor is currently the Chairman of StrarletDerma and Perfaction.
Mr. Cole is an experienced medical device executive, serving for 20 years in operational positions with American Hospital Supply, Baxter Healthcare, Scimed Life Systems, and Boston Scientific.
He is currently a partner with Spray Venture Partners, an early stage med-tech venture firm, and serves on the board of directors of Thoratec and several private companies.
Mr. Kariv is Co-founder and Chief Executive Officer of Pontifax, a group of Israeli-based life sciences venture funds focusing on investments in bio-pharmaceutical and med-tech technologies.
Mr. Kariv has also served as an active board member of many of the funds’ portfolio companies, assuming a special responsibility for strategic planning.
Mr. Kariv practiced law with Sullivan & Cromwell, a leading corporate law firm in New York, and holds a B.A. degree in Economics from Harvard University and a J.D. from Harvard Law School.
Mr. Sivan is the Founder, CEO of STI Laser Industries Ltd – leading medical device manufacturer, and Co-Founder of V-Wave and other medical device companies.
Mr. Sivan has a B.Sc. in Mechanical Engineering & M.B.A., Graduate – Israel Air Force Aviation Academy.
Prof. Abraham is director of the Division of Cardiovascular Medicine and a professor of internal medicine, physiology and cell biology at The Ohio State University Wexner Medical Center.
He also serves as Associate Director for Clinical and Translational Research at the Dorothy M. Davis Heart and Lung Research Institute.
Prof. Abraham is an internationally known researcher in heart failure. His research interests include hemodynamic and neurohormonal mechanisms in heart failure, sleep disordered breathing in heart failure, and clinical drug and device trials in heart failure and cardiac transplantation.
Prof. Abraham has participated as a site principal investigator in more than 100 multicenter clinical drug and device trials. He has also served as national or international principal investigator and on the steering committees of more than 30 multicenter clinical drug and device trials.
Dr. Zile is currently Professor of Medicine at the Medical University of South Carolina. He also serves as the Director of the Medical Intensive Care Unit at the Ralph H. Johnson Department of Veteran’s Affairs Medical Center in Charleston. He is an Adjunct Professor of Bioengineering at Clemson University.
Dr. Zile’s research career has involved both basic laboratory research examining the mechanisms of disease development and progression and translational clinical research examining the application of these basic mechanisms to development of effective treatment methods.
Dr. Zile is a recognized leader in the areas of cardiac function, congestive heart failure, diastolic heart failure and valvular heart disease.
Dr. Keren is director of the Cardiology Division at the Tel Aviv Sourasky Medical Center. He also serves as Professor of Cardiology at Tel-Aviv University’s Sackler School of Medicine since 1994.
Dr. Keren served in key medical roles in several innovative medical device companies. Prof. Keren has held the Chaim Sheba Chair of Cardiology at Tel Aviv University since 2005. He was a research fellow at the National Institutes of Health from 1989 to 1990.
Dr. Keren has written numerous patents in the field of cardiovascular therapeutics.
Dr. Amir is director of the Cardiology Department at Poriya Medical Center. He earned his medical degree from Ben-Gurion University Medical School in Israel, and completed his residency in internal medicine in Texas Medical Center, Houston.
Dr. Amir completes his fellowship in Cardiology and Heart Failure/Cardiac Transplantation at the Lady Davis Carmel Medical Center, Haifa. His research interests include endothelial function, Heart Failure clinical and genetics aspects, Oxidation in Heart Failure and Natriuretic peptides in heart failure.
Dr. Verheye has been a senior interventional cardiologist at the Antwerp Cardiovascular Center since 2000. He serves as a member of Scientific Advisory Board of several medical device manufacturers.
Dr. Verheye is a Fellow of the European Society of Cardiology, and a member of the Belgian Working Group on Interventional Cardiology and the European Association of Percutaneous Cardiovascular Interventions.
Dr. Zeevi is a physician specializing in interventional pediatric cardiology. He serves as a Managing General Partner at DFJ Tel Aviv Venture Partners, leading the fund Life Science and Cleantech investments and Co-Chairman of the Israel Advanced Technology Industries (IATI).
Dr. Zeevi is also the Founder and Co Director of an Executive Program for Biotechnology and Medical Device Entrepreneurs and Managers, at the Faculty of Management of Tel-Aviv University and serves on the advisory board of the Faculty.
Dr. Zeevi holds a M.D. degree (Magna Cum Laude) from the Sackler School of Medicine, Tel Aviv University, Israel. He was also a fellow, a visiting Professor and part-time clinical staff at the Children’s Hospital, Harvard Medical School in Boston.
